December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

25.90 -1.20 (-4.43%)
Streaming Delayed Price Updated: 3:31 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
StandardAero Surges In Market Debut ↗
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicara Therapeutics Inc.
Via GlobeNewswire
News headline image
Trio Of Biotech IPOs Climb In Debut ↗
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
Via Talk Markets
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.